Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis

Henry L Dorkin, Doris Staab, Elisabeth Operschall, Jeff Alder, Margarita Criollo, Henry L Dorkin, Doris Staab, Elisabeth Operschall, Jeff Alder, Margarita Criollo

Abstract

Background: Treatment of infective bronchitis involving Pseudomonas aeruginosa is a cornerstone of care in patients with cystic fibrosis (CF). This phase IIb, randomised, double-blind, placebo-controlled study assessed the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in this population.

Methods: Patients with CF, ≥12 years of age (N=286), were randomised to ciprofloxacin DPI (32.5 mg (n=93) or 48.75 mg (n=93)), or corresponding placebo (32.5 mg, n=65; 48.75 mg, n=35) twice daily for 28 days. The primary objective was the change in forced expiratory volume in 1 s (FEV1) from baseline (day 0) to end of treatment (day 29) in the intent-to-treat population for ciprofloxacin DPI compared with the corresponding placebo group.

Results: The primary effectiveness objective was not met; there were no significant differences in change in FEV1 between ciprofloxacin DPI and the corresponding placebo group for either dose (p=0.154). However, in pooled analyses, FEV1 decline from baseline to treatment end was significantly lower with ciprofloxacin DPI than with placebo (pooled data; p=0.02). Ciprofloxacin DPI showed positive effects on sputum bacterial load and quality of life, but these effects were not maintained at the 4-week follow-up. Ciprofloxacin DPI was well tolerated and there were no significant differences in type/incidence of treatment-emergent adverse events by treatment group (p=0.115).

Conclusions: Further investigations are needed to determine the full scope of the beneficial effects of ciprofloxacin DPI for patients with CF.

Trial registration number: Clinicaltrials.gov NCT00645788; EudraCT 2008-008314-40.

Keywords: Cystic Fibrosis.

Figures

Figure 1
Figure 1
Study design (A) and subject disposition (B). (A) Subjects were stratified based on maintenance macrolide usage and randomised 2:2:2:1 to receive twice daily: 32.5 mg ciprofloxacin DPI (corresponding to 50 mg dry powder); placebo corresponding to 32.5 mg ciprofloxacin DPI; 48.75 mg ciprofloxacin DPI (corresponding to 75 mg dry powder); or placebo corresponding to 48.75 mg ciprofloxacin DPI for 29 days (±1 day). DPI, dry powder for inhalation; EOT, end of treatment. (B) A total of 288 patients were randomised. Of these, 286 received either study drug or placebo, and were included in both the ITT and safety analyses sets. ITT, intent-to-treat.
Figure 2
Figure 2
Time course of FEV1 (mean, % predicted) (intent-to-treat population) by study group. Empirical mean FEV1 is presented as percentage predicted value, with error bars representing SD. DPI, dry powder for inhalation; FEV1, forced expiratory volume in 1 s.
Figure 3
Figure 3
Change in mean density of Pseudomonas aeruginosa in sputum (log10CFU/g) (intent-to-treat population) by study group. CFU, colony-forming unit; DPI, dry powder for inhalation.

References

    1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918–51.
    1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475–82.
    1. Cystic Fibrosis Foundation 2011 Patient Registry Report Cystic Fibrosis Foundation, 2011. (accessed Mar 2015).
    1. Flume PA, Robinson KA, O'Sullivan BP et al. . Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54:522–37.
    1. Bendiak GN, Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med 2009;30:587–95.
    1. Laube BL, Janssens HM, de Jongh FH et al. . What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308–31.
    1. Heijerman H, Westerman E, Conway S et al. . Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros 2009;8:295–15.
    1. Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J 2009;18:243–9.
    1. Geller DE, Konstan MW, Smith J et al. . Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307–13.
    1. Parkins MD, Elborn JS. Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011;5:609–22.
    1. Geller DE, Flume PA, Griffith DC et al. . Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011;55:2636–40.
    1. Novartis Pharmaceuticals Corporation. TOBI® PODHALER™ (tobramycin inhalation powder) TOBI® PODHALER™ (tobramycin inhalation powder) prescribing information 2013.
    1. Stass H, Nagelschmitz J, Kappeler D et al. . Lung deposition of ciprofloxacin dry powder for inhalation in healthy subjects and patients suffering from chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis. Poster presentation at International Congress of the American Thoracic Society; Philadelphia, USA, 2013.
    1. Gupta A, Tarara T, Miller D et al. . A novel high-payload dry powder formulation of ciprofloxacin for management of chronic lung infections. American Association of Pharmaceutical Scientists Annual Meeting; Washington, USA, 2011; Poster R6156.
    1. Weers JG, Tarara TE. The PulmoSphere™ platform for pulmonary drug delivery. Ther Deliv 2014;5:277–95.
    1. Stass H, Baumann-Noss S, Delesen H et al. . Pharmacokinetics of inhaled ciprofloxacin powder. 31st European Cystic Fibrosis Conference; Prague, Czech Republic, 2008; Poster P103.
    1. Wilson R, Welte T, Polverino E et al. . Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41:1107–15.
    1. Stass H, Nagelschmitz J, Willmann S et al. . Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig 2013;33:419–27.
    1. van Westreenen M, Tiddens HA. New antimicrobial strategies in cystic fibrosis. Paediatr Drugs 2010;12:343–52.
    1. Bayer HealthCare Pharmaceuticals. CIPRO® (ciprofloxacin hydrochloride) 2009.
    1. Bayer Plc. (Ciprofloxacin) Ciproxin tablets 500 mg Summary of Product Characteristics 2010.
    1. Bayer Plc. (Ciprofloxacin) Ciproxin Infusion Summary of Product Characteristics 2010.
    1. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011;9:32
    1. Herrmann G, Yang L, Wu H et al. . Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010;202:1585–92.
    1. Rao P, McCaughan J, McCalmont M et al. . Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients. J Cyst Fibros 2012;11:349–52.
    1. Alothman GA, Ho B, Alsaadi MM et al. . Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005;127:522–9.
    1. Geller DE, Nasr SZ, Piggott S et al. . Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care 2014;59:388–98.
    1. Stass H, Weimann B, Nagelschmitz J et al. . Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther 2013;35:1571–81.
    1. Stass H, Delesen H, Nagelschmitz J et al. . Safety and pharmaockinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. J Aerosol Med Pulm Drug Deliv 2015;28:106–15.
    1. Stass H, Nagelschmitz J, Kappeler D et al. . Lung deposition of Ciprofloxacin Dry Powder for Inhalation in healthy subjects and patients suffering from chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis (abstract). Am J Respir Crit Care Med 2013;187:A1507.
    1. Van Devanter D, Konstan M. Cystic fibrosis drug development: victims of our own success. Proc Resp Drug Deliv 2008;1:11–7.
    1. Stass H, Baumann-Noss S, Delesen H et al. . Ciprofloxacin PulmoSphere® inhalational powder: a healthy volunteer study. American Thoracic Society International Conference; Toronto, Canada, 2008; Poster G50.
    1. Geller DE, Flume PA, Staab D et al. . Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183:1510–16.
    1. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001;120:118S–23S.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever